COPENHAGEN (Reuters) - Zealand Pharma has begun Phase I trials on an experimental diabetes and obesity drug known as ZP2929, triggering a milestone payment from German partner Boehringer Ingelheim, the Danish biopharmaceutical company said on Thursday. The milestone payment would help to support future development of other diabetes drugs and treatments for people suffering from obesity, Zealand Pharma said. ... Click here to read the rest
No comments:
Post a Comment